# name
Mass treatment with single-dose azithromycin for yaws

# metadata.dc.description.abstract[].value
BACKGROUND: Mass treatment with azithromycin is a central
                component of the new World Health Organization (WHO) strategy to
                eradicate yaws. Empirical data on the effectiveness of the
                strategy are required as a prerequisite for worldwide
                implementation of the plan. METHODS: We performed repeated
                clinical surveys for active yaws, serologic surveys for latent
                yaws, and molecular analyses to determine the cause of skin
                ulcers and identify macrolide-resistant mutations before and 6
                and 12 months after mass treatment with azithromycin on a Papua
                New Guinean island on which yaws was endemic. Primary-outcome
                indicators were the prevalence of serologically confirmed active
                infectious yaws in the entire population and the prevalence of
                latent yaws with high-titer seroreactivity in a subgroup of
                children 1 to 15 years of age. RESULTS: At baseline, 13,302 of
                16,092 residents (82.7%) received one oral dose of azithromycin.
                The prevalence of active infectious yaws was reduced from 2.4%
                before mass treatment to 0.3% at 12 months (difference, 2.1
                percentage points; P<0.001). The prevalence of high-titer
                latent yaws among children was reduced from 18.3% to 6.5%
                (difference, 11.8 percentage points; P<0.001) with a
                near-absence of high-titer seroreactivity in children 1 to 5
                years of age. Adverse events identified within 1 week after
                administration of the medication occurred in approximately 17%
                of the participants, included nausea, diarrhea, and vomiting,
                and were mild in severity. No evidence of emergence of
                resistance to macrolides against Treponema pallidum subspecies
                pertenue was seen. CONCLUSIONS: The prevalence of active and
                latent yaws infection fell rapidly and substantially 12 months
                after high-coverage mass treatment with azithromycin, with the
                reduction perhaps aided by subsequent activities to identify and
                treat new cases of yaws. Our results support the WHO strategy
                for the eradication of yaws. (Funded by Newcrest Mining and
                International SOS; YESA-13 ClinicalTrials.gov number,
                NCT01955252.).

# metadata.dc.relation.ispartof[].value
The New England Journal of Medicine, 2015, vol. 372, num. 8, p. 703-710

# metadata.dc.source[].value
Articles publicats en revistes (ISGlobal)

# metadata.dc.title[].value
Mass treatment with single-dose azithromycin for yaws